Physician profile
Mark Matson Kaehr
NPI 1427361450
$451.15
in general payments reported to CMS, 2019-2025
12 companies · $21.16 in 2025
The $21.16 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $41.97 · 2021: $144 · 2022: $78.05 · 2023: $64.19 · 2025: $21.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $85.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $85.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $134.00 | 2021-2023 | Vabysmo |
| Alimera Sciences, INC. | $72.38 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $71.24 | 2019-2022 | |
| Eyepoint US, INC. | $35.35 | 2021-2022 | |
| Alcon Vision LLC | $30.62 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $28.26 | 2019-2020 | |
| Astellas Pharma US INC | $21.16 | 2025 | Izervay |
| Biogen, INC. | $16.30 | 2023 | |
| Abbvie INC. | $14.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.92 | 2021 | |
| Spark Therapeutics, INC. | $13.50 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kaehr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.